C. Tanaka

发表

Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants

H. Schran, C. Tanaka, O. Yin, 2011, Journal of clinical pharmacology.

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

K. Bhalla, H. Kantarjian, J. Cortes, 2006, The New England journal of medicine.

Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues.

M Rowland, M. Rowland, C. Tanaka, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats.

Y. Sugiyama, H. Suzuki, C. Tanaka, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.

W. Zhou, N. Gallagher, H. Schran, 2009, Clinical therapeutics.

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

C. Sotiriou, M. Piccart, C. Wouters, 2008, European journal of cancer.

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis

C. Tanaka, M. Sudoh, A. Katsume, 2013, International journal of experimental pathology.

Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human.

M Rowland, M. Rowland, C. Tanaka, 1998, The Journal of pharmacology and experimental therapeutics.

Clinical Pharmacology of Deferasirox

C. Tanaka, 2014, Clinical Pharmacokinetics.

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

H. Kantarjian, T. Smith, F. Giles, 2010, Clinical pharmacology and therapeutics.

Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial

M. McKeage, P. Fong, H. Schran, 2012, Cancer Chemotherapy and Pharmacology.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

H. Lane, E. Raymond, J. Kovarik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease

C. Tanaka, S. Sy, K. Grosch, 2022, Clinical Pharmacokinetics.

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

H. Kantarjian, J. Cortes, L. Alland, 2004 .

Abstract 751: Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial

M. McKeage, P. Fong, H. Schran, 2012 .

Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [14C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects.

V. Fischer, L. Alland, M. Kagan, 2005 .

Physiologically Based Pharmacokinetics of Cyclosporine A: Reevaluation of Dose–Nonlinear Kinetics in Rats

Ryosei Kawai, Malcolm Rowland, Chiaki Tanaka, 1999, Journal of Pharmacokinetics and Biopharmaceutics.

Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL).

K. Bhalla, H. Kantarjian, T. Smith, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cerebral infarction after deflation of a pneumatic tourniquet during total knee replacement.

C. Tanaka, H. Nakamura, Hitoshi Nakamura, 1999, Anesthesiology.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

H. Lane, E. Raymond, J. Kovarik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.